Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

Rituximab in Primary LPHD (RIPL) - First Line Therapy for Patients With Lymphocyte Predominant Hodgkin´s Disease (LPHD) in Clinical Stage IA Using the Monoclonal Anti-CD20 Antibody Rituximab.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00346684

Enrollment

Unknown

Registered

2006-06-30

Start date

2006-07-31

Completion date

Unknown

Last updated

2008-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)

Keywords

Lymphoma, LPHD, Rituximab

Brief summary

First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab

Interventions

DRUGRituximab

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* lymphocyte predominant Hodgkin´s lymphoma (histologically proven) * clinical stage IA (without risk factors: large mediastinal mass, extranodal involvement, ESR \> 50mm/h) * age 18 - 75 * WHO performance status 0-3 * normal organ function * written informed consent

Exclusion criteria

* classical Hodgkin´s lymphoma * composite lymphoma * leucocytes \< 3000/µl * thrombocytes \< 100.000/µl

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026